Riociguat (Adempas) approved for PAH and CTEPH (pulmonary hypertension)
www.pulmccm.org
Riociguat (Adempas) Gets FDA Indications for Pulmonary Hypertension That was fast. The US Food and Drug Administration (FDA) approved riociguat (brand name Adempas, by Bayer) for the treatment of pulmonary arterial hypertension (PAH) and the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), on October 8 2013.
Riociguat (Adempas) approved for PAH and CTEPH (pulmonary hypertension)
Riociguat (Adempas) approved for PAH and…
Riociguat (Adempas) approved for PAH and CTEPH (pulmonary hypertension)
Riociguat (Adempas) Gets FDA Indications for Pulmonary Hypertension That was fast. The US Food and Drug Administration (FDA) approved riociguat (brand name Adempas, by Bayer) for the treatment of pulmonary arterial hypertension (PAH) and the treatment of chronic thromboembolic pulmonary hypertension (CTEPH), on October 8 2013.